Ongoing clinical trials are exploring therapies like tolebrutinib, fingolimod, and ocrelizumab, focusing on efficacy and ...

NICE recommends natalizumab as a new treatment for adults with highly active relapsing-remitting multiple sclerosis ...

Scientists have used AI to identify two novel subtypes of multiple sclerosis (MS), which could offer new, targeted treatments ...

England's NICE is recommending natalizumab, sold as Tysabri and Tyruko, as an NHS-covered treatment option for people with ...

The ratio between two signaling molecules may be a key marker of MS brain inflammation and help identify candidates for BTK ...

Monoclonal antibody DMTs, especially anti-CD20 therapies, effectively prevent relapses but have limited impact on progressive MS. Progressive MS involves compartmentalized CNS inflammation, with ...

HOUSTON and WALTHAM, Mass., April 17, 2025 /PRNewswire/ -- Biostate AI, a leading innovator in artificial intelligence for RNA sequencing, today announced a strategic partnership with the Accelerated ...

Many people with multiple sclerosis struggle with balance and coordination, and this study uncovers a hidden reason why.

Artificial intelligence (AI), using a simple blood test combined with standard brain images has, for the first time, been ...

NICE has recommended the drug, natalizumab, as an option for adults with relapsing-remitting MS (RRMS) that remains highly active after a full course of at least one disease-modifying therapy, and for ...